V.K. Gadi, MD of @SeattleCCA answers commonly asked questions of the AVIATOR study and shares how it will affect future…
Browsing: Breast
Breast Cancer
V.K. Gadi, MD of @SeattleCCA discusses the AVIATOR study for HER2-positive metastatic breast cancer. __________ Read here:Â https://www.seattlecca.org/clinical-trials/breast-cancer-nct03414658
Address to Japan Society of Clinical Oncology focuseson opportunities to expand benefits to more patients Accomplished surgeon-scientist joined Roswell Park…
Peter O’Donnell, MD of @UChicagoMed provides results from biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab…
Peter O’Donnell, MD of @UChicagoMed explains biomarkers in patients with locally advanced metastatic urothelial carcinoma treated with durvalumab in phase…
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer provides information on trends in breast cancer death rates.
Carol DeSantis, MPH @caroldesantis6 of @AmericanCancer explains breast cancer trends in the U.S.
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs and how this…
Courtney Williams, MPH @cphilwil of @ONealCancerUAB explains findings in a new study that results in lower costs for patients with…
Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer. __________ Breast cancer is…
Zhibo Ma, PhD of @salkinstitute explains how this affects treatment and clinicians today. __________ Breast cancer is one of the…
Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer. ________…
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different…
Xiao-Ou Shu, MD of @VUMChealth explains how oncologists should treat male breast cancer patients and how it will affect clinicians.…
Research from the UAB’s O’Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had…
Xiao-Ou Shu, MD of @VUMChealth explains that in a recent study, men have a higher mortality rate than women due…
Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often…
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5…
With Breast Cancer Awareness Month Approaching, Cedars-Sinai Experts Discuss New Treatment Options for Early-Stage, Low-Risk Breast Cancer Patients LOS ANGELES…
Gregory Senofsky, MD of UCLA Health explains the standard conversion rate form lumpectomy to mastectomy. ______ FINDINGS Breast cancer surgeons…
Gregory Senofsky, MD of UCLA Health addresses how reducing the need for second surgery after lumpectomy will affect clinicians today…
Gregory Senofsky, MD of UCLA Health answers a question often asked by colleagues. ______ FINDINGS Breast cancer surgeons performing lumpectomies…
Gregory Senofsky, MD of UCLA Health explains the intraoperative teamwork that greatly reduces the need for second surgery after lumpectomy.…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center explains…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology shares the transition from volume to value in…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology describes the factors that influence cost in novel…
Debra Patt, MD, Executive Vice President, Strategic Initiatives, Academic Programs, Texas Oncology discusses the outcomes from the MONALEESA-7 trial in…
GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients
GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy
GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment
GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4
What To Discuss With Your Healthcare Team – a Diagnosis of Triple Negative Breast Cancer – Litton
What makes a triple negative breast cancer negative Reis Filho
Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid
Current Standard of Care in Triple Negative Breast Cancer – Yardley
Combination therapy IO Chemo in Triple Negative Breast Cancer Schmid
BRCA Mutations What does it Mean When Choosing My Treatment Litton
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase…
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial…
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares…
Neelima Denduluri MD, Associate Chair, US Oncology Research, Virginia Cancer Specialists explains the MONALESSA-7 trial outcomes in premenopausal metastatic breast…
Neelima Denduluri MD @ndenduluri1 Of US Oncology Research Discusses Updates On Patient Care From ASCO: New Ways To Educate Patients…
Scott Koenig, of Macrogenics, discusses what it will take to gain regulatory approval. About MacroGenics, Inc. MacroGenics is a clinical-stage…
Scott Koenig, of Macrogenics, discusses achieving a better outcome for patients. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…
Scott Koenig discusses the data on the Phase 3 SOPHIA study. About MacroGenics, Inc. MacroGenics is a clinical-stage biopharmaceutical company…